(Q40165422)

18 September 2017

Antistaphylococcal activity of LBM415, a new peptide deformylase inhibitor, compared with those of other agents (English)

1 reference

18 September 2017

Kim Credito

1

1 reference

18 September 2017

Gengrong Lin

series ordinal

2

1 reference

18 September 2017

Lois M Ednie

series ordinal

3

1 reference

18 September 2017

Peter C Appelbaum

series ordinal

4

1 reference

18 September 2017

language of work or name

English

0 references

publication date

1 October 2004

1 reference

Antimicrobial Agents and Chemotherapy

18 September 2017

1 reference

18 September 2017

48

1 reference

18 September 2017

10

1 reference

18 September 2017

4033-4036

1 reference

Vancomycin-resistant Staphylococcus aureus isolate from a patient in Pennsylvania

18 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=521910

Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=521910

Antipneumococcal and antistaphylococcal activities of ranbezolid (RBX 7644), a new oxazolidinone, compared to those of other agents

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=521910

In vitro activity of linezolid against multiply resistant Gram-positive clinical isolates.

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=521910

Comparative In vitro activities of daptomycin and vancomycin against resistant gram-positive pathogens

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=521910

Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=521910

Quinupristin/dalfopristin and linezolid: where, when, which and whether to use?

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=521910

In vitro activities of the glycylcycline GAR-936 against gram-positive bacteria

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=521910

22 September 2017

Oxazolidinones: a review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=521910

Optimal treatment of complicated skin and skin structure infections

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=521910

In vitro antibacterial activity of LY333328, a new semisynthetic glycopeptide

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=521910

Study of comparative antipneumococcal activities of penicillin G, RP 59500, erythromycin, sparfloxacin, ciprofloxacin, and vancomycin by using time-kill methodology

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=521910

Potential utility of a peptide deformylase inhibitor (NVP PDF-713) against oxazolidinone-resistant or streptogramin-resistant Gram-positive organism isolates

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=521910

Disk diffusion quality control guidelines for NVP-PDF 713: a novel peptide deformylase inhibitor

20 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=521910

In vitro activity of linezolid against staphylococci.

20 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=521910

Susceptibility of gram-positive cocci from 25 UK hospitals to antimicrobial agents including linezolid. The Linezolid Study Group.

20 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=521910

In vitro activity of linezolid against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae.

20 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=521910

The emergence of Staphylococcus aureus with reduced susceptibility to vancomycin in Japan

20 August 2018

1 reference

12 December 2020

Comparative spectrum and activity of NVP-PDF386 (VRC4887), a new peptide deformylase inhibitor

1 reference

12 December 2020

Quality control guidelines for MIC susceptibility testing of NVP PDF-713: a novel peptide deformylase inhibitor

1 reference

12 December 2020

Antimicrobial spectrum and activity of NVP PDF-713, a novel peptide deformylase inhibitor, tested against 1,837 recent Gram-positive clinical isolates

1 reference

12 December 2020

Commercial broth microdilution panel validation and reproducibility trials for NVP PDF-713 (LBM 415), a novel inhibitor of bacterial peptide deformylase

1 reference

12 December 2020

Methicillin-resistant Staphylococcus aureus in Europe

1 reference

12 December 2020

10.1128/AAC.48.10.4033-4036.2004

Identifiers

DOI

1 reference

18 September 2017

1 reference

18 September 2017

PubMed publication ID

15388473

1 reference